loading
Schlusskurs vom Vortag:
$8.60
Offen:
$8.68
24-Stunden-Volumen:
306.84K
Relative Volume:
0.99
Marktkapitalisierung:
$415.53M
Einnahmen:
$36.90M
Nettoeinkommen (Verlust:
$-166.28M
KGV:
-2.6444
EPS:
-3.29
Netto-Cashflow:
$-203.53M
1W Leistung:
+1.64%
1M Leistung:
+22.54%
6M Leistung:
-32.97%
1J Leistung:
-64.40%
1-Tages-Spanne:
Value
$8.51
$8.91
1-Wochen-Bereich:
Value
$8.205
$9.0702
52-Wochen-Spanne:
Value
$6.10
$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name
Firmenname
Bicycle Therapeutics Plc Adr
Name
Telefon
011441223261503
Name
Adresse
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Name
Mitarbeiter
305
Name
Twitter
@Bicycle_tx
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BCYC's Discussions on Twitter

Vergleichen Sie BCYC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BCYC
Bicycle Therapeutics Plc Adr
8.70 595.58M 36.90M -166.28M -203.53M -3.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-08 Eingeleitet Stephens Equal-Weight
2024-09-06 Eingeleitet RBC Capital Mkts Outperform
2024-08-07 Herabstufung B. Riley Securities Buy → Neutral
2023-09-11 Hochstufung B. Riley Securities Neutral → Buy
2022-08-31 Eingeleitet Cowen Outperform
2022-07-28 Eingeleitet Barclays Overweight
2022-07-06 Fortgesetzt Canaccord Genuity Buy
2022-04-13 Herabstufung B. Riley Securities Buy → Neutral
2022-04-07 Fortgesetzt Cantor Fitzgerald Overweight
2022-02-14 Eingeleitet Morgan Stanley Equal-Weight
2021-12-17 Eingeleitet SVB Leerink Outperform
2021-12-09 Eingeleitet Needham Buy
2021-09-30 Eingeleitet B. Riley Securities Buy
2021-04-20 Eingeleitet JMP Securities Mkt Outperform
2020-10-12 Eingeleitet Cantor Fitzgerald Overweight
2020-06-12 Eingeleitet Oppenheimer Outperform
2020-04-17 Eingeleitet H.C. Wainwright Buy
2019-11-14 Eingeleitet ROTH Capital Buy
2019-09-11 Hochstufung Goldman Neutral → Buy
2019-06-17 Eingeleitet Canaccord Genuity Buy
2019-06-17 Eingeleitet Goldman Neutral
2019-06-17 Eingeleitet Jefferies Buy
2019-06-17 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten

pulisher
Jul 17, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

William Blair Brokers Decrease Earnings Estimates for TLX - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Boosts Stake in Capri Holdings Limited (NYSE:CPRI) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World

Jul 17, 2025
pulisher
Jul 04, 2025

The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World

Jul 04, 2025
pulisher
Jun 22, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World

Jun 22, 2025
pulisher
May 26, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com India

May 26, 2025
pulisher
May 07, 2025

Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX

May 07, 2025
pulisher
May 01, 2025

Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa

May 01, 2025
pulisher
Apr 24, 2025

How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com

Apr 23, 2025
pulisher
Apr 07, 2025

Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 07, 2025
pulisher
Apr 05, 2025

Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India

Apr 05, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK

Apr 04, 2025
pulisher
Mar 31, 2025

Bicycle Therapeutics stock hits 52-week low at $8.6 amid downturn By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India

Mar 27, 2025
pulisher
Mar 24, 2025

Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 12, 2025

Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India

Mar 12, 2025
pulisher
Mar 03, 2025

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.

Mar 03, 2025
pulisher
Feb 25, 2025

Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Jan 15, 2025

Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India

Jan 15, 2025
pulisher
Jan 13, 2025

Bicycle Therapeutics reports promising cancer drug trial results - Investing.com

Jan 13, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics exec sells $30k in shares - Investing.com

Jan 06, 2025
pulisher
Oct 23, 2024

Bicycle Therapeutics spotlights cancer treatment targets - Investing.com

Oct 23, 2024
pulisher
Oct 14, 2024

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - Yahoo Finance

Oct 14, 2024
pulisher
Oct 07, 2024

Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK

Oct 07, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics CEO sells shares worth over $71k - Investing.com

Oct 04, 2024
pulisher
Jul 14, 2024

South Korea Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research

Jul 14, 2024
pulisher
Jun 21, 2024

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio - Yahoo Finance

Jun 21, 2024
pulisher
May 24, 2024

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert (NASDAQ:BCYC) - Seeking Alpha

May 24, 2024

Finanzdaten der Bicycle Therapeutics Plc Adr-Aktie (BCYC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):